# Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

> **NCT03994107** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pegylated Liposomal Doxorubicin
- **DRUG:** Albumin-bound paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT03994107
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994107, "Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03994107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*